Status:
UNKNOWN
HLA Analysis in Autoimmune Encephalitis and Related Disorders
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Autoimmune Encephalitis
Imbic Encephalitis
Eligibility:
All Genders
18+ years
Brief Summary
Autoimmune encephalitis (AE) are characterized by subacute onset of memory deficits, altered mental status or psychiatric symptoms, frequently associated with seizures, inflammatory cerebrospinal flui...
Eligibility Criteria
Inclusion
- Presence of anti-LGI1, anti-CASPR2 or anti-GAD antibodies in serum or cerebrospinal fluid;
- Clinical picture compatible with the detected antibody (limbic encephalitis in anti-LGI1; limbic encephalitis, neuromyotonia or Morvan's syndrome in anti-CASPR2; limbic encephalitis, cerebellar ataxia or stiff-person syndrome in anti-GAD
Exclusion
- \- Absence of complete clinicobiological data.
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04106596
Start Date
October 1 2019
End Date
October 1 2020
Last Update
September 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes
Lyon, France